Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions (EBS) disclosed an insider administrative transaction by its EVP and Chief Financial Officer. On 10/15/2025, 4,995 common shares were withheld (Transaction Code F) at $9.6 to cover taxes upon vesting and settlement of restricted stock units. After this transaction, the officer directly beneficially owns 291,497 shares.
Emergent BioSolutions (EBS) executive Michael M. Trova, EVP, Quality & Ethics, and CPL, sold 30,608 shares of common stock at $10.00 on 10/07/2025 pursuant to a Rule 10b5-1(c) trading plan adopted on December 2, 2024. Following the sale, he beneficially owns 144,319 shares.
The filing notes it was submitted late due to an inadvertent administrative error.
Emergent BioSolutions filed a Form 144 reporting a proposed sale of 30,608 common shares with an aggregate market value of $306,080.00, which are to be sold through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 10/07/2025. The filing shows the shares were received as restricted stock in multiple grants from the issuer between 04/07/2023 and 12/08/2024, with the largest single grant listed as 26,779 shares on 12/08/2024. The filer represents no undisclosed material nonpublic information and reports no sales of issuer securities in the past three months.
Emergent BioSolutions entered into a new, material agreement with the U.S. government tied to its smallpox vaccine. On September 5, 2025, a contract modification from the Office of the Assistant Secretary for Preparedness and Response exercised Option Year 6 under the existing 10-year ACAM2000® contract. The modification is valued at $56 million and requires Emergent to deliver doses of its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government by December 31, 2025.
The company also referenced that the full text of this modification will be filed with its next quarterly report, and that the base ACAM2000 contract is already on file as a material agreement. In a related move, Emergent issued a press release on September 9, 2025 describing the modification, which is attached as an exhibit to this report for investors seeking additional detail.
Emergent BioSolutions Inc. disclosed a new government order for its anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). On August 29, 2025, the company received Modification No. 20 to its existing BARDA AV7909 Contract with the Biomedical Advanced Research and Development Authority, providing for procurement of additional CYFENDUS doses valued at $30.0 million.
The underlying BARDA AV7909 Contract, originally effective September 30, 2016 and amended several times, supports development and procurement of this anthrax vaccine. Emergent also issued a press release on September 2, 2025 describing the modification, and filed the full text of Modification No. 20 and the press release as exhibits.
Kathryn C. Zoon, a director of Emergent BioSolutions, reported the sale of 7,086 shares of Emergent common stock on 08/15/2025 at an exact price of $8.87 per share. After the transaction she beneficially owned 71,799 shares. The filing states the shares were sold under a Rule 10b5-1 trading plan dated May 16, 2025 to satisfy tax obligations arising from RSU vesting on May 22 and May 25, 2025. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Emergent Biosolutions (EBS) reported a Form 144 notice to sell restricted common stock. The filing shows an intended sale of 7,086 shares with an aggregate market value of $62,852.82, representing part of a total 53,351,099 shares outstanding. The proposed approximate sale date is 08/15/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The shares to be sold were acquired as restricted stock: 6,101 shares on 05/08/2025 and 985 shares on 05/25/2025, with payment recorded on the acquisition dates. The filer reports no securities sold by the same person during the past three months and makes the required representation about material nonpublic information.
Donald W. DeGolyer, a director of Emergent BioSolutions (EBS), sold 7,844 shares of common stock on 08/12/2025 at an exact price of $8.6475 per share to satisfy tax obligations arising from the settlement of vested restricted stock units (RSUs) on 05/22/2025. After this tax-withholding sale the reporting person directly beneficially owns 137,659 shares. The filing lists the transaction code "S" and provides the explanation that the sale was executed solely to satisfy tax withholding related to the RSU settlement.
Emergent Biosolutions (EBS) filed a Form 144 reporting a proposed sale of 7,844 shares of common stock that were acquired as restricted stock from the issuer on 05/08/2025. The filing lists an aggregate market value of $67,830.99 for the shares and shows 53,351,099 shares outstanding for the issuer. The seller reports an approximate date of sale of 08/12/2025 and the transaction is to occur on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The form indicates no securities sold in the past three months by the person for whose account these securities are to be sold and includes the standard representation that the signer does not possess undisclosed material adverse information about the issuer.